Morgan Stanley sets USD 977.00 target for McKesson stock

Published on 10/13/2026 at 11:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

McKesson agreed to invest USD 1.4 billion for 49 percent of Option Care. McKesson stock traded at EUR 856.90 on October 13, 2026.

Key points in brief

Morgan Stanley maintained an Overweight rating and a USD 977.00 target for McKesson stock, according to a report dated October 9, 2026.
McKesson agreed on October 6, 2026, to invest USD 1.4 billion for a 49 percent stake in Option Care Health.
First-quarter fiscal 2027 revenue reached USD 105.4 billion, while adjusted earnings per share rose 20 percent to USD 9.93.
McKesson stock was trading at EUR 856.90 at Lang & Schwarz on October 13, 2026, at 11:42 a.m. CEST.
McKesson is listed on the NYSE and is a member of the S&P 500.

3D-Render eines modernen Glas-Bürogebäudes mit Grünanlage und Vorplatz — Architektur-Render eines modernen Hauptsitz-Gebäudes symbolisiert McKesson Corporation ISIN US58155Q1031 im Gesundheitssektor mit großer Glasfassade, Illustration mit AI erstellt.

McKesson stock (ISIN US58155Q1031) was trading at EUR 856.90 at Lang & Schwarz on October 13, 2026, at 11:42 a.m. CEST. According to Yahoo Finance on October 9, 2026, Morgan Stanley maintained an Overweight rating and a USD 977.00 price target for McKesson.

Analyst target reaches USD 977.00

The target gives the market a clear valuation reference while McKesson builds out specialty healthcare services. The report also cited first-quarter fiscal 2027 revenue of USD 105.4 billion, up 8 percent year over year, and adjusted earnings per share of USD 9.93, up 20 percent.

TickerScout reported that GAAP diluted earnings per share were USD 5.15 in the first quarter of fiscal 2027, down from USD 6.25 a year earlier, after a USD 293.0 million redemption-value adjustment tied to the Medical-Surgical Solutions transaction.

What the Option Care deal means

On October 6, 2026, McKesson and Clayton Dubilier & Rice agreed to acquire Option Care Health for USD 32.05 per share and an enterprise value of USD 5.8 billion. McKesson will invest USD 1.4 billion for a 49 percent minority interest, while CD&R will hold 51 percent, according to McKesson.

The transaction extends McKesson's reach into home and alternate-site infusion services. Its strategic value rests on adding specialty-care capabilities, while the financial outcome depends on regulatory approval, shareholder approval and the integration of a new minority investment.

Three dated company milestones

On August 5, 2026, McKesson reported fiscal 2027 first-quarter revenue of USD 105.4 billion and raised adjusted earnings-per-share guidance to USD 44.20-45.00 from USD 43.80-44.60, according to TickerScout. On September 14, 2026, McKesson reiterated fiscal 2027 adjusted earnings-per-share guidance of USD 44.20-45.00 at the Morgan Stanley healthcare conference, as Investing.com reported. On October 6, 2026, the company announced the USD 5.8 billion Option Care transaction.

Next dates carry concrete conditions

McKesson is scheduled to report second-quarter fiscal 2027 results on November 4, 2026, according to Simply Wall St. The Option Care transaction is expected to close in the first half of calendar 2027, subject to customary approvals, according to McKesson.

Stock value and trading context

McKesson had a market capitalization of USD 111.9 billion as of October 12, 2026. Its primary-market 52-week range was USD 723.68 to USD 999.00, placing the latest USD quote inside a broad valuation corridor.

The stock's immediate investment debate therefore combines a USD 977.00 Morgan Stanley target with an acquisition that adds specialty-care exposure. The next earnings report will test whether the USD 44.20-45.00 adjusted earnings-per-share outlook remains supported by operating results.

McKesson stock at Lang & Schwarz

McKesson stock was trading at EUR 856.90 at Lang & Schwarz on October 13, 2026, at 11:42 a.m. CEST. The reference price is shown without a percentage comparison because the dated Xetra close required for the article's reference base was not established. The further course of trading is shown by the continuously updated real-time quote of McKesson stock.